Educational research on US and Indian equities, ETFs, mutual funds and crypto, with screeners and a free investing academy.
All data is for educational purposes only and should not be considered investment advice.
Equiscale is operated by Syntellia LLC, a Delaware limited liability company.
© 2026 Syntellia LLC. All rights reserved.
Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, siRNA platform, gene therapy, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 45 skipping; and ELEVIDYS, an AAV-based gene therapy, which is contraindicated in patients with any deletion in exon 8 and/or exon 9 in the Duchenne gene. The company also develops SRP-9003, a gene therapy program for the treatment of LGMD2E; SRP-1001 to selectively target and knockdown DUX4 using RNAi in Phase 1/2a clinical trials; and SRP-1003 for reduction of expression of the DMPK gene in Phase 1/2a clinical trials. It has collaboration and license agreements with F. Hoffman-La Roche Ltd; Arrowhead Pharmaceuticals, Inc.; University of Western Australia; Nationwide Children's Hospital; Hansa Biopharma; and Duke University. The company was incorporated in 1980 and is headquartered in Cambridge, Massachusetts.
Rule-based from financial data. Not advice.
5-year financial trends. Figures in USD millions.
Latest fiscal year: 2025
Year-by-year revenue, profitability, and cash flow (USD millions, last 5 years)
| Year | Revenue | EBITDA | Net Profit | FCF | ROE | Rev Growth 1Y | NP Growth 1Y |
|---|---|---|---|---|---|---|---|
| 2025 | $2.2B | $-620M | $-713M | $-315M | -62.5% | 15.6% | -403.3% |
| 2024 | $1.9B | $317M | $235M | $-353M | 15.4% | 53.0% | -143.9% |
| 2023 | $1.2B | $-454M | $-536M | $-588M | -62.4% | 33.3% | -23.8% |
| 2022 | $933M | $-595M | $-703M | $-358M | -182.7% | - | - |
| 2021 |
Income statement, balance sheet, and cash flow as reported
Consolidated Figures in USD Millions.
| Metric | 2025 |
|---|---|
| Total Revenue | 2,198.24 |
| Operating Revenue | 2,198.24 |
| Cost Of Revenue | 839.60 |
| Gross Profit | 1,358.63 |
| Operating Expense | 2,016.40 |
| Research And Development | 1,522.07 |
| Selling General And Administration | 491.72 |
| Total Expenses | 2,856.01 |
| Operating Income | -657.77 |
| Total Operating Income As Reported | -699.78 |
| EBITDA | -619.56 |
| Normalized EBITDA | -578.50 |
| EBIT | -664.08 |
| Interest Income | 36.69 |
| Interest Expense | 38.14 |
| Net Interest Income | -1.45 |
| Other Non Operating Income Expenses | -1.94 |
| Other Income Expense | - |
| Interest Income Non Operating | 36.69 |
| Interest Expense Non Operating | 38.14 |
| Net Non Operating Interest Income Expense | -1.45 |
| Pretax Income | -702.22 |
| Tax Provision | 11.18 |
| Tax Rate For Calcs | 0 |
| Tax Effect Of Unusual Items | -8.62 |
| Net Income Continuous Operations | -713.41 |
| Net Income From Continuing And Discontinued Operation | -713.41 |
| Net Income From Continuing Operation Net Minority Interest | -713.41 |
| Net Income | -713.41 |
| Net Income Common Stockholders | -713.41 |
| Net Income Including Noncontrolling Interests | -713.41 |
| Normalized Income | -680.97 |
| Diluted NI Availto Com Stockholders | -713.41 |
| Basic Average Shares | 93.62 |
| Diluted Average Shares | 97.49 |
| Reconciled Depreciation | 44.52 |
| Reconciled Cost Of Revenue | 797.71 |
| Total Unusual Items | -41.06 |
| Total Unusual Items Excluding Goodwill | -41.06 |
| Special Income Charges | -25.15 |
| Other Special Charges | -16.86 |
| Write Off | 0 |
| Impairment Of Capital Assets | - |
| Restructuring And Mergern Acquisition | 42.01 |
| Gain On Sale Of Security | -15.91 |
| Depreciation Amortization Depletion Income Statement | 2.62 |
| Depreciation And Amortization In Income Statement | 2.62 |
| General And Administrative Expense | 491.72 |
| Other Gand A | 262.27 |
| Salaries And Wages | 229.45 |
| Gain On Sale Of Ppe | - |
| Amortization | 2.62 |
| Amortization Of Intangibles Income Statement | 2.62 |
| Securities Amortization | - |
Healthcare sector peers, ranked by market cap
| Company | Ticker | Market Cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|---|
| Sarepta Therapeutics, Inc.this co. | SRPT | $1.8B | -2.47 | 1.54 | -62.5% | -3.22 |
| TransMedics Group, Inc. | TMDX | $2.5B | 12.96 | 5.21 | 40.2% | 16.82 |
| Acadia Healthcare Company, Inc. | ACHC | $2.3B | -2.10 | 1.19 | -56.6% | -6.55 |
| Prestige Consumer Healthcare Inc. | PBH | $2.2B | 11.31 | 1.14 | 10.1% | 9.47 |
| LeMaitre Vascular, Inc. | LMAT |
| - |
| - |
| - |
| - |
| - |
| - |
| - |
| $2.1B |
| 37.03 |
| 5.43 |
| 14.7% |
| 25.28 |
| Select Medical Holdings Corporation | SEM | $2.0B | 13.99 | 1.20 | 8.6% | 9.20 |
| Neogen Corporation | NEOG | $2.0B | -1.82 | 0.96 | -52.7% | -2.94 |
| ADMA Biologics, Inc. | ADMA | $1.8B | 12.59 | 3.87 | 30.8% | 9.31 |
| Phibro Animal Health Corporation | PAHC | $1.3B | 27.77 | 4.69 | 16.9% | 13.79 |
| Peer Median | - | 12.78 | 2.54 | 12.4% | 9.39 | |